Why drugs for 'orphan' diseases are a booming business with colossal costs for patients - The Globe and Mail
![Alexion to Acquire Synageva to Strengthen Global Leadership in Developing and Commercializing Transformative Therapies for Patients with Devastating and Rare Diseases | Business Wire Alexion to Acquire Synageva to Strengthen Global Leadership in Developing and Commercializing Transformative Therapies for Patients with Devastating and Rare Diseases | Business Wire](https://mms.businesswire.com/media/20150506005445/en/466413/5/2233430_Alexion_Logo_-_Color.jpg)
Alexion to Acquire Synageva to Strengthen Global Leadership in Developing and Commercializing Transformative Therapies for Patients with Devastating and Rare Diseases | Business Wire
![Aaron Blocker on Twitter: "One year ago today I started #Strensiq injections to treat my #Hypophosphatasia I've given myself 6 injections a week for a year 😳 I've noticed small improvements but Aaron Blocker on Twitter: "One year ago today I started #Strensiq injections to treat my #Hypophosphatasia I've given myself 6 injections a week for a year 😳 I've noticed small improvements but](https://pbs.twimg.com/media/EACR2kuX4AApdoQ.jpg)
Aaron Blocker on Twitter: "One year ago today I started #Strensiq injections to treat my #Hypophosphatasia I've given myself 6 injections a week for a year 😳 I've noticed small improvements but
![Life Saving Drugs Program – Asfotase alfa (Strensiq®) outcome statement | Australian Government Department of Health and Aged Care Life Saving Drugs Program – Asfotase alfa (Strensiq®) outcome statement | Australian Government Department of Health and Aged Care](https://www.health.gov.au/sites/default/files/styles/h_content_max_width_no_upscale/public/images/publications/2020/10/life-saving-drugs-program-asfotase-alfa-strensiq-outcome-statement.jpg?itok=qAjUHd8u)